SREBF1 and metabolic dysfunction-associated steatotic liver disease: Indeed, clinical studies using LXR agonists were hindered by the development of non-alcoholic fatty liver diseases (NAFLD), since LXR is also an activator of the transcription factor SREBP1 (gene name: SREBF1) that induces hepatic lipogenesis via fatty acid synthase26.